Primary and secondary outcomes with mGFR (<65 vs ≥65)
| . | Hazard ratio (95% CI) . | P . |
|---|---|---|
| Nonrelapse mortality | ||
| Day 0-100 | 4.17 (0.84-20.0) | .081 |
| Day 0-1 y | 3.12 (1.28-7.69) | .012 |
| Overall | 2.13 (1.03-4.35) | .040 |
| Relapse | ||
| Day 0-100 | 0.63 (0.01-6.46) | .74 |
| Day 0-1 y | 0.98 (0.21-4.56) | .98 |
| Overall | 1.46 (0.33-6.46) | .62 |
| Engraftment | ||
| Day 0-100 | 0.80 (0.50-1.28) | .36 |
| Acute/chronic GVHD | ||
| Day 0-100 | 1.27 (0.62-2.56) | .52 |
| Day 0-1 y | 1.20 (0.71-2.08) | .48 |
| Chronic GVHD | ||
| Day 0-1 y | 0.92 (0.45-1.89) | .81 |
| Overall | 0.98 (0.52-1.82) | .94 |
| Infection | ||
| Day 0-100 | 2.78 (1.56-5.00) | <.001 |
| Day 0-1 y | 2.63 (1.54-4.55) | <.001 |
| . | Hazard ratio (95% CI) . | P . |
|---|---|---|
| Nonrelapse mortality | ||
| Day 0-100 | 4.17 (0.84-20.0) | .081 |
| Day 0-1 y | 3.12 (1.28-7.69) | .012 |
| Overall | 2.13 (1.03-4.35) | .040 |
| Relapse | ||
| Day 0-100 | 0.63 (0.01-6.46) | .74 |
| Day 0-1 y | 0.98 (0.21-4.56) | .98 |
| Overall | 1.46 (0.33-6.46) | .62 |
| Engraftment | ||
| Day 0-100 | 0.80 (0.50-1.28) | .36 |
| Acute/chronic GVHD | ||
| Day 0-100 | 1.27 (0.62-2.56) | .52 |
| Day 0-1 y | 1.20 (0.71-2.08) | .48 |
| Chronic GVHD | ||
| Day 0-1 y | 0.92 (0.45-1.89) | .81 |
| Overall | 0.98 (0.52-1.82) | .94 |
| Infection | ||
| Day 0-100 | 2.78 (1.56-5.00) | <.001 |
| Day 0-1 y | 2.63 (1.54-4.55) | <.001 |